GLP-1 Pipeline Update: November 2025 Quarterly view of the GLP-1 pipeline and anticipated indications Editorial team Maryam Tabatabai, PharmD Editor-In-Chief Associate Vice President, Clinical Information Carole Kerzic, RPh Executive Editor Drug Information Pharmacist Principal Nicole Kjesbo, PharmD, BCPS Executive Editor Clinical Program Development Director Senior, Pipeline DISCLAIMER The drug pipeline is fluid
Taking Ozempic for weight loss is an off-label indication and should only be done after careful consideration and under the guidance of a healthcare provider
GLP-1 is an incretin hormone naturally produced in the intestinal L-cells in response to food intake
"Semaglutide and cardiovascular outcomes in obesity without diabetes." N Engl J Med
Clinical trials have indicated weight loss of 15-20% with lifestyle changes, establishing semaglutide as a leading weight loss medication
Wegovy can cost from $0-$1,500+ per month for American consumers